GLP-1 receptor agonists, such as semaglutide, have revolutionized obesity management by effectively reducing body weight predominantly through appetite suppression and improved glycemic control. However, a significant limitation of this class of drugs is their associated loss of lean mass—up to 40% of total weight lost during treatment can be from muscle tissue, which may compromise patients’ metabolic health and physical function. The introduction of bimagrumab, which antagonizes the activin type II receptors to promote muscle growth and inhibit muscle wasting, offers a compelling solution to this challenge.

The BELIEVE study meticulously evaluated the efficacy and safety of semaglutide alone, bimagrumab alone, and their combination, over a sustained treatment period of 72 weeks. Participants were randomly assigned to one of nine groups, encompassing two dosages of bimagrumab (10 mg/kg and 30 mg/kg administered every 12 weeks) combined with two dosages of semaglutide (1.0 mg and 2.4 mg administered weekly), or the individual administration of each agent. This robust design enabled a comprehensive assessment of dose-dependent responses and the additive impact on body composition.

Remarkably, individuals treated solely with bimagrumab experienced an average weight loss of 10.8%, which was exclusively attributed to fat mass reduction, paralleled by an unexpected 2.5% increase in lean mass. Conversely, participants receiving semaglutide alone shed an average of 15.7% of their body weight, with 71.8% of this loss derived from fat mass, indicating that lean mass depletion was still a concern. Most notably, the cohort administered the combination therapy demonstrated an impressive average weight loss of 22.1%, with a predominant 92.8% of weight loss from fat mass, while lean mass was substantially preserved.

These findings underscore the potential of the combination therapy to circumvent the deleterious loss of skeletal muscle commonly seen with GLP-1 receptor agonists, thereby optimizing metabolic outcomes and physical functionality among patients with obesity. Dr. Heymsfield emphasized, “Our data reveal that bimagrumab and semaglutide operate through distinct yet complementary biological pathways. When combined, they maximize fat loss and for the first time in large clinical trials, demonstrate significant lean mass retention alongside profound weight reduction.”

Beyond weight loss metrics, the study elucidated systemic metabolic improvements associated with the treatment regimens. Participants showed up to an 83% reduction in high-sensitivity C-reactive protein (hsCRP), a robust biomarker for systemic inflammation and cardiovascular risk. Furthermore, there was a substantial elevation in adiponectin levels, a hormone intimately involved in enhancing insulin sensitivity, fostering lipid metabolism, and exerting anti-inflammatory effects, which collectively contribute to cardiometabolic health.

In a clinically relevant subgroup exhibiting prediabetic markers at baseline, the combination therapy achieved a 100% reversion rate to normoglycemia among some dosing groups, effectively normalizing glucose homeostasis in this at-risk population. This result highlights the potential utility of the drug duo not only in weight management but also in the prevention of type 2 diabetes progression.

Safety and tolerability profiles were largely consistent with prior experience of the individual agents. Adverse events reported in the bimagrumab arms, such as mild-to-moderate acne and muscle spasms, warrant further investigation to optimize dosing and minimize side effects. The study’s double-blind, placebo-controlled design lends strong credibility to these conclusions while advocating continued clinical exploration to refine this promising therapeutic strategy.

Importantly, these results advocate for a paradigm shift in obesity treatment evaluation, moving beyond conventional weight and body mass index (BMI) metrics toward more precise assessments of body composition. Emphasizing lean body mass preservation in clinical outcomes acknowledges the multidimensional complexity of obesity and the metabolic consequences of tissue-specific weight changes.

Funded by Eli Lilly and Company and orchestrated under the auspices of Versanis Bio—a Lilly subsidiary—this trial signifies a collaboration between industry and academic research, fostering innovation in metabolic medicine. The Pennington Biomedical Research Center continues to spearhead multidisciplinary investigations into metabolic disorders, leveraging extensive clinical infrastructure and expertise.

As obesity prevalence escalates globally and current therapeutic options grapple with limitations, the synergistic administration of semaglutide and bimagrumab offers renewed hope for patients and clinicians alike. This approach, combining an appetite-suppressing incretin analog with a muscle-preserving activin antagonist, may redefine standards of care, emphasizing both fat mass reduction and muscle conservation.

Future research trajectories will focus on long-term durability of these effects, mechanistic insights into tissue-specific pathways modulated by the drug combination, and broader evaluations in diverse patient populations. As personalized medicine evolves, therapies targeting multiple biological axes might emerge as indispensable tools in tackling obesity’s multifaceted challenges.

The clinical implications of this study extend beyond weight metrics, encompassing cardiovascular risk mitigation, inflammation reduction, and diabetes prevention. It heralds a new era where preserving metabolic health and functionality through tailored pharmacological combinations becomes paramount in obesity management.

In conclusion, the BELIEVE phase 2 trial’s compelling demonstration that semaglutide and bimagrumab, alone but particularly in concert, yield significant and sustained weight loss with preservation of lean mass marks a critical milestone. This dual-action therapy holds transformative promise and is poised to influence future discourses and treatments in metabolic health sciences.

Subject of Research: People

Article Title: Bimagrumab plus semaglutide alone or in combination for the treatment of obesity: a randomized phase 2 trial

News Publication Date: March 5, 2026

Web References:
– https://www.nature.com/articles/s41591-026-04204-0
– http://www.pbrc.edu

References:
Heymsfield, S.B., et al. “Bimagrumab and semaglutide alone or in combination for the treatment of obesity: a phase 2 randomized clinical trial.” Nature Medicine, 2 March 2026, DOI: 10.1038/s41591-026-04204-0.

Keywords: Obesity, GLP-1 receptor agonist, semaglutide, bimagrumab, activin signaling blockade, lean mass preservation, randomized controlled trial, metabolic health, weight loss, inflammation, adiponectin, prediabetes

Obesity represents one of the most pressing public health crises globally, especially in high-income countries where sedentary lifestyles and caloric surplus dominate. The World Health Organization reports a dramatic tripling in worldwide adult obesity rates since 1975, with 2.5 billion adults currently classified as overweight and nearly 900 million living with obesity as of 2022. Against this backdrop, the search for effective, sustainable weight management strategies remains urgent. Intermittent fasting, with its alluring simplicity and purported metabolic benefits, suggests an appealing solution—but does the rigorous scientific record support such enthusiasm?

Examining evidence from 22 randomized controlled trials encompassing almost 2,000 participants across diverse geographic populations—including North America, Europe, China, Australia, and South America—the Cochrane team focused on several intermittent fasting protocols. These ranged from alternate-day fasting (where participants fast every other day) to periodic fasting (fasting for specific days each month) and time-restricted feeding (limiting daily eating windows). Most trials maintained intervention periods of up to 12 months to assess mid-term effectiveness.

The findings demonstrated that intermittent fasting’s impact on body weight was statistically indistinguishable from that of conventional dietary advice, which typically advocates for controlled calorie intake and improved nutritional quality. Moreover, intermittent fasting did not outperform control groups who received no specific dietary intervention. These results suggest that the much-ballyhooed benefits of fasting regimens may not translate into significantly greater weight loss or metabolic improvement in overweight or obese adults.

One complicating factor identified in the review was the inconsistency and limited reporting of adverse effects associated with intermittent fasting. Without standardized documentation of side effects such as hunger, fatigue, headaches, or potential impacts on psychological well-being, it remains challenging to fully understand the safety profile of fasting interventions. The relatively small sample sizes and heterogeneous methodologies of the included studies further constrain the evidence base, underscoring the need for more rigorous and extensive clinical trials.

Luis Garegnani, lead author of the review from the Universidad Hospital Italiano de Buenos Aires Cochrane Associate Centre, emphasizes the sobering reality: intermittent fasting “just doesn’t seem to work for overweight or obese adults trying to lose weight” any better than more traditional means. This statement is a crucial corrective to the online hype that often portrays fasting as a near-miraculous solution, suggesting that the enthusiasm far outpaces what is currently supported by empirical data.

There is also a pressing need for research that extends beyond short-term trials. Obesity is a chronic and multifaceted condition requiring interventions that demonstrate durable effectiveness over years rather than months. Current studies often cover periods insufficient to understand long-term adherence, metabolic adaptation, or weight regain, limiting their utility for informing clinical practice and public health policies.

An additional concern raised by the review is the demographic skew of existing research participants. The majority of subjects were from predominantly white populations in high-income countries, leaving significant gaps in data for ethnically diverse populations or those residing in low- and middle-income countries. This gap constrains generalizability, as factors such as genetic background, cultural dietary habits, socioeconomic status, and healthcare infrastructure can influence obesity management outcomes significantly.

Moreover, the effects of intermittent fasting may vary based on biological and behavioral variables such as sex, age, comorbid conditions, and mental health status, including eating disorders. Without stratified analyses or adequately powered studies that can dissect these interactions, healthcare providers are left without clear guidelines tailored to individual patient profiles.

Eva Madrid, senior author from the Cochrane Evidence Synthesis Unit Iberoamerica, advocates for a personalized approach in light of these complexities. Rather than issuing broad recommendations, clinicians must evaluate the unique circumstances, preferences, and medical histories of patients before suggesting intermittent fasting or any other dietary regimen. Such nuanced care is critical to ensuring both effectiveness and safety in weight management strategies.

The review also touches on the role of the mass media in shaping public perceptions of intermittent fasting. Social media platforms have facilitated rapid dissemination of fasting protocols without sufficient emphasis on scientific validation or acknowledgment of potential risks. This phenomenon underscores the necessity for public health communications to balance engaging narratives with evidence-based information, helping to temper unrealistic expectations and encourage informed decision-making.

In sum, while intermittent fasting remains a popular and potentially viable option for some individuals seeking weight control, current evidence fails to substantiate claims of superior efficacy compared to conventional dietary approaches. As research continues to evolve, emphasis should pivot toward large-scale, long-duration trials with diverse populations and rigorous safety monitoring to better delineate whom, if anyone, might benefit most from such regimens.

Until then, healthcare professionals and patients alike should critically assess intermittent fasting’s promises in the context of established nutritional science. The allure of quick fixes must be weighed against the realities of complex metabolic processes and the multifactorial nature of obesity, advocating for holistic lifestyle interventions that are sustainable, evidence based, and tailored to individual needs.

Subject of Research: People
Article Title: Intermittent fasting for adults with overweight or obesity
News Publication Date: 15-Feb-2026
Web References: Cochrane Database DOI: 10.1002/14651858.CD015610.pub2
Keywords: Weight loss, Foods, Metabolic disorders, Nutrition disorders, Body mass index, Obesity, Nutritional physiology, Nutrients, Nutrition, Starvation, Diseases and disorders, Mass media, Society, Demography, Human population, Clinical studies